PDF(Pubmed)
Abstract：
Cancer represents a significant global health and economic burden due to its high mortality rates. While effective in some instances, traditional chemotherapy often falls short of entirely eradicating various types of cancer. It can cause severe side effects due to harm to healthy cells. Two therapeutic approaches have risen to the forefront to address these limitations: metronomic chemotherapy (MCT) and drug repurposing. Metronomic chemotherapy is an innovative approach that breaks from traditional models. It involves the administration of chemotherapeutic regimens at lower doses, without long drug-free intervals that have previously been a hallmark of such treatments. This method offers a significant reduction in side effects and improved disease management. Simultaneously, drug repurposing has gained considerable attraction in cancer treatment. This approach involves utilizing existing drugs, initially developed for other therapeutic purposes, as potential cancer treatments. The application of known drugs in a new context accelerates the timeline from laboratory to patient due to pre-existing safety and dosage data. The intersection of these two strategies gives rise to a novel therapeutic approach named \'Metronomics.\' This approach encapsulates the benefits of both MCT and drug repurposing, leading to reduced toxicity, potential for oral administration, improved patient quality of life, accelerated clinical implementation, and enhanced affordability. Numerous clinical studies have endorsed the efficacy of metronomic chemotherapy with tolerable side effects, underlining the potential of Metronomics in better cancer management, particularly in low- and middle-income countries. This review underscores the benefits and applications of metronomic chemotherapy and drug repurposing, specifically in the context of breast cancer, showcasing the promising results of pre-clinical and clinical studies. However, we acknowledge the necessity of additional clinical investigations to definitively establish the role of metronomic chemotherapy in conjunction with other treatments in comprehensive cancer management.
摘要：
由于其高死亡率,癌症代表了重大的全球健康和经济负担。虽然在某些情况下有效，传统化疗往往不能完全根除各种癌症。由于对健康细胞的伤害，它可能会引起严重的副作用。两种治疗方法已经上升到解决这些限制的最前沿：节拍化疗（MCT）和药物再利用。节制化疗是一种创新的方法，打破了传统模式。它涉及低剂量的化疗方案，没有以前是这种治疗标志的长期无药间隔。该方法提供了副作用的显著降低和改善的疾病管理。同时,药物再利用在癌症治疗中获得了相当大的吸引力。这种方法涉及利用现有药物，最初开发用于其他治疗目的，作为潜在的癌症治疗方法。由于预先存在的安全性和剂量数据，已知药物在新环境中的应用加速了从实验室到患者的时间表。这两种策略的交集产生了一种名为“Metronomics”的新颖治疗方法。这种方法囊括了MCT和药物再利用的好处，导致毒性降低，口服给药的潜力，改善患者生活质量，加快临床实施，和增强的负担能力。许多临床研究已经认可了节拍化疗的疗效，具有可耐受的副作用，强调了Metronomics在更好的癌症管理中的潜力，特别是在低收入和中等收入国家。这篇综述强调了节拍化疗和药物再利用的益处和应用。特别是在乳腺癌的背景下，展示临床前和临床研究的有希望的结果。然而,我们承认有必要进行额外的临床研究,以明确确定节拍化疗与其他治疗方法在癌症综合治疗中的作用.
